0.88% -0.84

Pre-mercato: 99.85 5.56 +5.90%

Revvity Inc (RVTY)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché RVTY Giù? Forum Previsione Frazionamento azionario Storia dei dividendi

Revvity Inc (RVTY)

Revvity Inc Borsa (RVTY) Ultime notizie

Revvity: Q1 Earnings Snapshot - Greenwich Time

Revvity beats quarterly estimates on steady demand for medical equipment - Reuters

(RVTY) Revvity Expects Full-Year 2025 Revenue Range $2.83B$2.87B, vs. FactSet Est of $2.83B - marketscreener.com

Revvity Crushes Q1 Earnings Expectations with 67% EPS Growth, Raises 2025 Revenue Outlook - Stock Titan

Revvity (RVTY) Q1 Earnings Report Preview: What To Look For - The Globe and Mail

Revvity’s Quarterly Earnings Preview: What You Need to Know - MSN

Segmental Performance to Drive RVTY's Q1 Earnings: Is a Beat Likely? - MSN

Why Revvity (RVTY) Could Beat Earnings Estimates Again - Yahoo Finance

Press Release Distribution & PR Platform - ACCESS Newswire

Calculating The Fair Value Of Revvity, Inc. (NYSE:RVTY) - simplywall.st

Earnings Preview For Revvity - Benzinga

Revvity Keeps Quarterly Dividend at $0.07 a Share, Payable August 8 to Holders of Record July 18 - marketscreener.com

Lobbying Update: $30,000 of REVVITY INC. lobbying was just disclosed - Nasdaq

Revvity Board Declares Quarterly Dividend - Business Wire

Revvity Board Declares Quarterly Dividend | RVTY Stock News - GuruFocus

Revvity Continues Steady Dividend Program: $0.07 Per Share Coming This August - Stock Titan

Revvity to Unveil VivoJect Image-guided Injection System at AACR - Genetic Engineering and Biotechnology News

Watchmaker Genomics and Revvity Team to Automate and Streamline NGS Library Preparation - Genetic Engineering and Biotechnology News

Revvity’s Quarterly Earnings Preview: What You Need To Know - Barchart.com

High Content Screening and Imaging Market Set for 8.4% CAGR Through 2029 - GlobeNewswire Inc.

Revvity (RVTY) Price Target Cut by Baird Ahead of Q1 Results | R - GuruFocus

Revvity Fuels the Future of Cancer Science with New Research Solutions - Business Wire

Assessing Revvity: Insights From 6 Financial Analysts - Benzinga

Earnings Preview: Revvity (RVTY) Q1 Earnings Expected to Decline - Yahoo Finance

Revvity (RVTY) Price Target Cut by Baird Ahead of Q1 Results | RVTY Stock News - GuruFocus

Bernstein Adjusts Price Target on Revvity to $120 From $140, Maintains Market Perform Rating - marketscreener.com

Revvity price target lowered to $120 from $140 at Bernstein - TipRanks

Lab equipment giant ensnared in sprawling $300M fraud case over failed testing tools - Crain's Chicago Business

Revvity (RVTY) Faces Price Target Cut Amid Funding Concerns | RV - GuruFocus

Ex-Dividend Reminder: Revvity, Dime Community Bancshares and First Busey - Nasdaq

What Is Revvity, Inc.'s (NYSE:RVTY) Share Price Doing? - Yahoo Finance

BofA Reduces Revvity (RVTY) Price Target Amid Policy Challenges - GuruFocus

BofA Securities Cuts Price Target on Revvity to $116 From $143, Maintains Buy Rating - MarketScreener

BofA Reduces Revvity (RVTY) Price Target Amid Policy Challenges | RVTY Stock News - GuruFocus

KeyBanc Lowers Price Target on Revvity to $135 From $145 - MarketScreener

Choosing a flexible digital platform for drug discovery - Scientific Computing World

Barclays Adjusts Revvity (RVTY) Price Target Ahead of Q1 Earnings | RVTY Stock News - GuruFocus

Barclays Adjusts Price Target on Revvity to $110 From $140 - MarketScreener

KeyBanc maintains Overweight rating on Revvity stock at $145 target - Investing.com Australia

KeyBanc maintains Overweight rating on Revvity stock at $145 target By Investing.com - Investing.com South Africa

KeyBanc Adjusts Price Target on Revvity to $145 From $135, Keeps Overweight Rating - MarketScreener

Tecan expands portfolio for specialty diagnostics with an asset purchase relating to certain ELISA kits - the-scientist.com

Why We're Not Concerned About Revvity, Inc.'s (NYSE:RVTY) Share Price - simplywall.st

Revvity Signals Software Unveils Unified Data Platform To Accelerate Drug Discovery - Technology Networks

Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test - Technology Networks

Here's Why You Should Retain Revvity Stock in Your Portfolio for Now - MSN

Revvity Q1 2025 Earnings Preview: CEO and CFO to Detail Financial Performance - Stock Titan

FDA approves Revvity’s Auto-Pure platform and tuberculosis test combo - Yahoo

Tecan Expands Portfolio for Specialty Diagnostics With an Asset Purchase Relating to Certain ELISA Kits - Business Wire

Revvity (RVTY) Gains FDA Approval for Automated TB Test - GuruFocus

FDA greenlights Revvity’s TB diagnostic platform By Investing.com - Investing.com South Africa

What's Going On With Revvity Stock Today? - Benzinga

(RVTY) Investment Analysis - news.stocktradersdaily.com

Simile a RVTY